Browsing Tag
ACHIEVE-1
1 post
Lilly’s oral GLP-1 drug orforglipron cuts A1C and body weight in type 2 diabetes Phase 3 trial
Eli Lilly’s once-daily oral GLP-1 therapy orforglipron delivered significant A1C and weight reductions in Phase 3 ACHIEVE-1 trial, with safety aligned to injectables.